StockData

Baird Medical Investment vs Beyond Air

BDMD and XAIR side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How BDMD and XAIR compare

Beyond Air grew revenue faster over the last twelve months (60.7% versus −39.2% for Baird Medical Investment).

Baird Medical Investment keeps more of each dollar of sales as profit, with a net margin of −121% compared with −436% at Beyond Air.

Beyond Air scores higher on the StockData Score (6 against 2 for Baird Medical Investment), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricBDMDXAIR
Size and price
Market cap–$1.9M
Share price$0.092$2.01
Change, 1 year−92.8%−92.7%
Change, 5 years–−100.0%
Beta (5Y)3.10−0.20
Employees14654
StockData Score
Total score26 (better)
Valuation score03 (better)
Growth score02 (better)
Performance score00
Health score2 (better)1
Dividend score00
Valuation
P/S–0.3×
P/B–1.0×
FCF yield–−1018%
Fair value–$12.88
Margin of safety–84.4%
Growth
Revenue growth (TTM)−39.2%60.7% (better)
Revenue growth, 5Y average–54.5%
Net income growth (TTM)−319%–
EPS growth (TTM)−272%–
Profitability
Gross margin83.8% (better)4.2%
Operating margin−114% (better)−365%
Net margin−121% (better)−436%
FCF margin−6.2% (better)−255%
Return on equity−77.5% (better)−562%
Return on invested capital−48.2%–
Financial health
Debt / equity0.22–
Interest coverage−72.3×−6.3× (better)
Current ratio1.293.31 (better)
Altman Z-score–−15.90
Piotroski F-score16 (better)
Dividends and buybacks
Shareholder yield–0.00%
Ownership
Held by institutions–7.2%
Held by insiders62.0%–
Insider net buying, 12 months–$287K

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.